In particular, we found higher values of IGF-I x ULN at baseline, more frequent large pituitary tumors and more frequent resistance to first generation SSA in patients with active acromegaly during treatment with c-Peg-V as compared to those reported in patients that reached the disease control. Here, IGF1 is linked to acromegaly.